Our findings also suggest that the discrepancies in the literature regarding dopamine transporter availability in ADHD participants (some studies reporting increases, other no changes and other decreases) may reflect, in part, differences in treatment histories. The gene discussed is SLC6A3; the disease is attention deficit-hyperactivity disorder.